A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Abexinostat (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms RENAVIV
- Sponsors Xynomic Pharmaceuticals
- 08 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 20 Mar 2019 According to a Xynomic Pharmaceuticals media release, the company will sponsor an investigator meeting to bring together European Union physicians, care providers and clinical research coordinators on 22 Mar 2019.
- 16 Mar 2019 According to a Xynomic media release, the authorities of China, Spain and Poland have approved to conduct this study. The company plans to initiate this trial in China, Spain, Poland and additional European countries in the first half of 2019.